Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Clinuvel Pharmaceuticals ( (AU:CUV) ).
CLINUVEL PHARMACEUTICALS LTD has announced that its Annual General Meeting (AGM) will be held on October 17, 2025, with the Notice of Meeting to be lodged by September 15, 2025. This announcement is part of the company’s compliance with ASX Listing Rule 3.13.1, which also sets September 5, 2025, as the closing date for director nominations. The AGM is a significant event for shareholders, providing an opportunity to engage with the company’s strategic direction and governance.
The most recent analyst rating on (AU:CUV) stock is a Hold with a A$14.00 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.
More about Clinuvel Pharmaceuticals
CLINUVEL PHARMACEUTICALS LTD is a global specialty pharmaceutical group headquartered in Melbourne, Australia, focusing on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening acute disorders. The company is a pioneer in photomedicine and melanocortin peptides, offering innovative treatments for systemic photoprotection, DNA repair, and repigmentation. Its lead therapy, SCENESSE®, is approved for use in Europe, the USA, Israel, and Australia.
Average Trading Volume: 112,385
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$533.8M
Learn more about CUV stock on TipRanks’ Stock Analysis page.